Cargando…
Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
It is strongly suggested that dipeptidyl peptidase‐4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor use is required in daily diabetes care.[Ima...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717917/ https://www.ncbi.nlm.nih.gov/pubmed/30989811 http://dx.doi.org/10.1111/jdi.13060 |